Spots Global Cancer Trial Database for metastatic triple negative breast cancer
Every month we try and update this database with for metastatic triple negative breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| S 81694 Plus Paclitaxel in Metastatic Breast Cancer | NCT03411161 | Metastatic Brea... Metastatic Trip... | Combination the... Paclitaxel Combination the... | 18 Years - | Servier | |
| Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | NCT04739670 | Metastatic Trip... | Atezolizumab Bevacizumab Gemcitabine Carboplatin | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | NCT03577743 | Metastatic Trip... Safety Issues Efficacy | Bevacizumab | 18 Years - 75 Years | Assiut University | |
| Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer | NCT04111510 | Metastatic Trip... | Tumor infiltrat... | 18 Years - | Yale University | |
| Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors | NCT01936961 | Metastatic Non-... Metastatic Colo... Metastatic Trip... | CTLA-4 Antibody Hypofractionate... | 18 Years - | Western Regional Medical Center | |
| Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | NCT04739670 | Metastatic Trip... | Atezolizumab Bevacizumab Gemcitabine Carboplatin | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. | NCT05181462 | Triple Negative... | Carboplatin Gemcitabine Nadunolimab | 18 Years - | Cantargia AB | |
| An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer | NCT01130259 | Breast Cancer | iniparib | 18 Years - | Sanofi | |
| Leflunomide in Previously Treated Metastatic Triple Negative Cancers | NCT03709446 | Breast Neoplasm... Breast Diseases Metastatic Trip... | Leflunomide | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | NCT03256344 | Metastatic Trip... Metastatic Colo... | Talimogene Lahe... Atezolizumab | 18 Years - 99 Years | Amgen | |
| To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | NCT03330847 | Metastatic Trip... | Olaparib Contin... Ceralasertib 16... Adavosertib 150... | 18 Years - 130 Years | AstraZeneca | |
| Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | NCT03577743 | Metastatic Trip... Safety Issues Efficacy | Bevacizumab | 18 Years - 75 Years | Assiut University | |
| Leflunomide in Previously Treated Metastatic Triple Negative Cancers | NCT03709446 | Breast Neoplasm... Breast Diseases Metastatic Trip... | Leflunomide | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer | NCT01238952 | Advanced Solid ... Metastatic Trip... | NK012 and carbo... | 18 Years - | Nippon Kayaku Co., Ltd. | |
| Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | NCT02555657 | Metastatic Trip... | pembrolizumab capecitabine eribulin gemcitabine vinorelbine | 18 Years - | Merck Sharp & Dohme LLC | |
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer | NCT05029999 | Metastatic Trip... | PLD Chemotherap... CDX-1140 CDX-301 | 18 Years - 99 Years | University of Texas Southwestern Medical Center | |
| Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | NCT03256344 | Metastatic Trip... Metastatic Colo... | Talimogene Lahe... Atezolizumab | 18 Years - 99 Years | Amgen | |
| Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer | NCT02158507 | Metastatic Trip... | Combination of ... | 19 Years - | University of Alabama at Birmingham | |
| Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | NCT03121352 | Metastatic Trip... | Carboplatin Nab-paclitaxel Pembrolizumab | 18 Years - | Case Comprehensive Cancer Center | |
| Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) | NCT01881230 | Breast Tumor Breast Cancer Cancer of the B... Estrogen Recept... HER2- Negative ... Progesterone Re... Recurrent Breas... Stage IV Breast... Triple-negative... Triple-negative... Metastatic Brea... | nab-Paclitaxel Carboplatin Gemcitabine | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
